Biochemical Biomarkers in Early Disease Detection: A Systematic Review of Molecular Basis and Clinical Applications
Salamat Academic & Research Journal · 24.03.2026 · 3 (1) · 127-148
DOI: 10.61438/sarj.v3i1.260 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Salamat Academic & Research Journal, online erschienen am 24.03.2026. Verfasst von Mohammad Ehsan Salehi. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Aims
This systematic review aimed to evaluate the role of biochemical biomarkers in early disease diagnosis and therapeutic monitoring, with emphasis on their molecular basis, clinical relevance, and translational potential.
Methods
This systematic review was conducted in accordance with the PRISMA 2020 guidelines and structured using the PICO framework. A comprehensive literature search was performed in PubMed, Scopus, Web of Science, ScienceDirect, and Google Scholar for studies published between 2000 and 2025. Eligible English-language randomized controlled trials and clinical studies investigating biochemical biomarkers for disease diagnosis or management were included. Study selection involved duplicate removal, title and abstract screening, and full-text assessment, conducted independently by two reviewers.
Results
The evidence indicated that inflammatory, oxidative stress–related, metabolic, enzymatic, and disease-associated protein biomarkers can detect early molecular and cellular alterations preceding clinical manifestations. For example, inflammatory biomarkers such as C-reactive protein in cardiovascular disease and metabolic markers such as HbA1c in diabetes have demonstrated utility in early or subclinical disease detection, defined as the stage prior to overt clinical manifestation. Where available, diagnostic performance indicators such as sensitivity and specificity were considered. These biomarkers demonstrated potential utility in subclinical disease detection, risk stratification, and early therapeutic monitoring. However, challenges related to limited specificity, biological variability, and methodological heterogeneity were frequently reported.
Conclusion
Biochemical biomarkers represent key tools in the advancement of early, preventive, and personalized medicine. Future progress depends on the integration of multi-biomarker panels, omics-based technologies, artificial intelligence–driven analysis, and robust clinical validation to support their routine clinical application.
Zitieren
APA
Salehi, M. E. (2026). Biochemical Biomarkers in Early Disease Detection: A Systematic Review of Molecular Basis and Clinical Applications. Salamat Academic & Research Journal, 3(1), 127-148. https://doi.org/10.61438/sarj.v3i1.260
Vancouver
Salehi ME. Biochemical Biomarkers in Early Disease Detection: A Systematic Review of Molecular Basis and Clinical Applications. Salamat Academic & Research Journal. 2026;3(1):127-148. doi:10.61438/sarj.v3i1.260
BibTeX
@article{Salehi2026,
author = {Salehi, Mohammad Ehsan},
title = {Biochemical Biomarkers in Early Disease Detection: A Systematic Review of Molecular Basis and Clinical Applications},
journal = {Salamat Academic & Research Journal},
year = {2026},
volume = {3},
number = {1},
pages = {127--148},
doi = {10.61438/sarj.v3i1.260}
}
EUVIMED